Media coverage about Imprimis Pharmaceuticals (NASDAQ:IMMY) has trended positive this week, according to Alpha One Sentiment Analysis. The research group, a unit of Accern, rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a coverage optimism score of 0.31 on Alpha One’s scale. Alpha One also assigned media coverage about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the next several days.

Insider Buying and Selling by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) traded down 2.59% during midday trading on Friday, hitting $3.01. The company had a trading volume of 105,207 shares. The stock has a 50 day moving average price of $3.63 and a 200 day moving average price of $3.00. The firm’s market capitalization is $60.40 million. Imprimis Pharmaceuticals has a 1-year low of $1.65 and a 1-year high of $4.69.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last issued its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.07. The firm had revenue of $6.10 million during the quarter, compared to the consensus estimate of $6.50 million. Imprimis Pharmaceuticals had a negative return on equity of 388.64% and a negative net margin of 90.48%. On average, equities analysts anticipate that Imprimis Pharmaceuticals will post ($0.86) EPS for the current fiscal year.

IMMY has been the topic of a number of analyst reports. Rodman & Renshaw reiterated a “buy” rating and issued a $5.00 price target on shares of Imprimis Pharmaceuticals in a research report on Wednesday, March 22nd. Zacks Investment Research raised Imprimis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Friday, March 24th. Finally, ValuEngine downgraded Imprimis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 16th.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/06/16/imprimis-pharmaceuticals-immy-given-daily-news-impact-score-of-0-31-updated.html.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Receive News & Stock Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.